Eyenovia Announces Securities Purchase Agreement
Exciting news from Eyenovia!
What’s the latest?
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 40,170,050 shares of common stock in a registered direct offering at a combined offering price of $0.0969 per share and accompanying warrants. The warrants will have an exercise price of $0.0969 per share, will be exercisable commencing six months from the date of issuance or, if required by The Nasdaq Capital Market, upon receipt of approval of the Company’s stockholders, and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about December 9, 2024, subject to the satisfaction of customary closing conditions.
This is a significant development for Eyenovia as they continue to grow and expand their presence in the ophthalmic technology market. The securities purchase agreement will provide the company with additional resources to further develop and commercialize their innovative products, ultimately benefiting both the company and its customers.
How will this affect you?
As a potential investor or consumer of Eyenovia’s products, this news could have a direct impact on you. The company’s increased financial resources and focus on developing advanced technologies could lead to the creation of more effective and efficient ophthalmic solutions. This could mean better treatment options and improved outcomes for individuals with eye conditions.
How will this affect the world?
Eyenovia’s continued growth and innovation in the ophthalmic technology sector could have a broader impact on the world. By providing advanced products and solutions for eye care, Eyenovia is contributing to the overall advancement of healthcare technology and improving the quality of life for individuals with eye-related health issues. This could lead to a brighter future for individuals worldwide who are in need of better eye care options.
Conclusion
In conclusion, Eyenovia’s announcement of a securities purchase agreement is a positive step forward for the company and the field of ophthalmic technology. With increased resources and a focus on innovation, Eyenovia is poised to make a significant impact on the industry and the world as a whole.
